Evidence map›Paper›PMID 31069131›Full record

ArticleOncoimmunology

A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects

Valeria Governa, Alvaro Brittoli, Valentina Mele, Maurizio Pinamonti, Luigi Terracciano, Simone Muenst, Giandomenica Iezzi, Giulio Cesare Spagnoli, Paul Zajac, Emanuele Trella

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Valeria GovernaDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Alvaro BrittoliDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy.ORCID 0000-0002-0459-4198
Valentina MeleDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Maurizio PinamontiUnit of Pathology, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.ORCID 0000-0002-9277-9378
Luigi TerraccianoInstitute of Pathology, Basel University Hospital and University of Basel, Basel, Switzerland.
Simone MuenstInstitute of Pathology, Basel University Hospital and University of Basel, Basel, Switzerland.
Giandomenica IezziDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Giulio Cesare SpagnoliDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Paul ZajacDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
Emanuele TrellaDepartment of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
University of Basel · CHUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD40 triggering may result in antitumor effects of potentially high clinical relevance. To gain insights important for patient selection and to identify adequate targeting techniques, we investigated CD40 expression in human cancer tissues and generated a replication-incompetent recombinant vaccinia virus expressing CD40 ligand (rVV40L). Its effects were explored

Indexed as

cancer immunotherapyCD40 pathwaycellular immune responsesmacrophagesrecombinant vaccinia virus

Identifiers

PMID31069131
PMCPMC6492963
OpenAlexW2912042538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.